{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.191","value":"2.32"},{"groupId":"OG001","spread":"14.949","value":"-0.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.452","value":"0.62"},{"groupId":"OG001","spread":"15.849","value":"-1.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.888","value":"1.98"},{"groupId":"OG001","spread":"16.147","value":"-1.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.577","value":"1.25"},{"groupId":"OG001","spread":"18.903","value":"-0.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.562","value":"2.91"},{"groupId":"OG001","spread":"14.766","value":"2.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.669","value":"4.14"},{"groupId":"OG001","spread":"16.811","value":"0.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"88"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.815","value":"5.32"},{"groupId":"OG001","spread":"17.635","value":"1.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.296","value":"7.26"},{"groupId":"OG001","spread":"18.059","value":"3.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"35"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.220","value":"5.07"},{"groupId":"OG001","spread":"17.063","value":"7.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.440","value":"4.10"},{"groupId":"OG001","spread":"17.993","value":"8.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.485","value":"5.24"},{"groupId":"OG001","spread":"17.378","value":"3.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.662","value":"5.90"},{"groupId":"OG001","spread":"18.561","value":"7.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.880","value":"6.23"},{"groupId":"OG001","spread":"18.885","value":"5.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Cycle 27 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.314","value":"7.53"},{"groupId":"OG001","spread":"21.037","value":"5.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 30 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.330","value":"5.17"},{"groupId":"OG001","spread":"22.573","value":"5.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Cycle 33 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.710","value":"8.72"},{"groupId":"OG001","spread":"24.186","value":"4.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 36 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.669","value":"8.65"},{"groupId":"OG001","spread":"22.384","value":"6.64"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 39 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The FACT-BMT is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family, and emotional well-being, together with additional concerns relevant for bone marrow transplantation participants. The questions were based on a 5-point Likert scale, where 0 corresponds to \"not at all\" and 4 corresponds to \"very much.\" The higher the final score, the better the quality of life. The FACT-BMT total score ranges from 0 to 148.","dispersionType":"Standard Deviation","groups":[{"description":"Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).","id":"OG000","title":"Ruxolitinib"},{"description":"Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.","id":"OG001","title":"Best Available Therapy"}],"paramType":"MEAN","populationDescription":"FAS. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)","title":"Change From Baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}